# Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

> **NCT05125055** · PHASE2,PHASE3 · RECRUITING · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 80 (estimated)

## Conditions studied

- Oral Squamous Cell Carcinoma
- Neoadjvant Therapy
- Anti-PD-1
- Chemotherapy

## Interventions

- **DRUG:** Toripalimab (anti-programmed death-1 inhibitor)
- **DRUG:** Albumin paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Docetaxel
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT05125055
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05125055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05125055, "Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05125055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*